Payment overview · 2025
General Payments
$992.18
50 reported records · 22 companies
Healthcare provider profile · identity verified
David Anson Martin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITEVILLE, NC · NPI 1639131022
Verified facts
What the public records show
CMS Open Payments records show David Anson Martin, MD received $992.18 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 512 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 512 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $232.74 | 23.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.38 | 9.4% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $91.05 | 9.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.19 | 8.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.61 | 6.5% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.88 | 5.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.07 | 5.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.06 | 4.4% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.27 | 3.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $34.45 | 3.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.66 | 2.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.20 | 1.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.40 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.11 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.77 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.37 | 1.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $15.77 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.75 | 1.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.77 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.26 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.92 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.50 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $992.18 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $193.07 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.47 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $91.05 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $70.41 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.61 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $53.87 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $52.88 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.50 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $44.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $44.06 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.06 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.66 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 512 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 202 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
202 | 47 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
512 | 85 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
512 | 85 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1225 | 299 |
| Gabapentin | Gabapentin | 1188 | 223 |
| Amlodipine Besylate | Amlodipine Besylate | 911 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 772 | 180 |
| Pantoprazole Sodium | Pantoprazole Sodium | 734 | 176 |
| Furosemide | Furosemide | 630 | 162 |
| Potassium Chloride | Potassium Chloride | 581 | 141 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 529 | 77 |
| Omeprazole | Omeprazole | 517 | 119 |
| Eliquis | Apixaban | 512 | 85 |
| Losartan Potassium | Losartan Potassium | 507 | 119 |
| Fluticasone Propionate | Fluticasone Propionate | 447 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 428 | 108 |
| Tramadol Hcl | Tramadol Hcl | 388 | 83 |
| Lisinopril | Lisinopril | 384 | 90 |
| Metformin Hcl | Metformin Hcl | 342 | 88 |
| Carvedilol | Carvedilol | 339 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 339 | 72 |
| Oxycodone Hcl | Oxycodone Hcl | 333 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 314 | 80 |
| Allopurinol | Allopurinol | 294 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 289 | 68 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 283 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 276 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 86 |
| Alprazolam | Alprazolam | 269 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 241 | 86 |
| Donepezil Hcl | Donepezil Hcl | 230 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 229 | 44 |
| Linzess | Linaclotide | 202 | 47 |
| Clonazepam | Clonazepam | 201 | 33 |
| Montelukast Sodium | Montelukast Sodium | 200 | 37 |
| Mirtazapine | Mirtazapine | 192 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 189 | 37 |
| Sertraline Hcl | Sertraline Hcl | 188 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 169 | 37 |
| Methylprednisolone | Methylprednisolone | 167 | 114 |
| Hydralazine Hcl | Hydralazine Hcl | 163 | 41 |
| Simvastatin | Simvastatin | 160 | 37 |
| Baclofen | Baclofen | 158 | 46 |
| Trazodone Hcl | Trazodone Hcl | 151 | 35 |
| Meloxicam | Meloxicam | 145 | 26 |
| Famotidine | Famotidine | 143 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 24 |
| Ezetimibe | Ezetimibe | 136 | 30 |
| Pregabalin | Pregabalin | 129 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 126 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 34 |
| Levetiracetam | Levetiracetam | 115 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 34 |
| Lorazepam | Lorazepam | 109 | 22 |
| Aripiprazole | Aripiprazole | 105 | 17 |
| Prednisone | Prednisone | 104 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 34 |
| Xarelto | Rivaroxaban | 103 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 19 |
| Jardiance | Empagliflozin | 94 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 90 | 19 |
| Latanoprost | Latanoprost | 89 | 16 |
| Azithromycin | Azithromycin | 85 | 68 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 31 |
| Memantine Hcl | Memantine Hcl | 83 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 18 |
| Colchicine | Colchicine | 82 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 80 | 17 |
| Valsartan | Valsartan | 79 | 16 |
| Benazepril Hcl | Benazepril Hcl | 78 | 11 |
| Atenolol | Atenolol | 77 | 17 |
| Finasteride | Finasteride | 77 | 21 |
| Spironolactone | Spironolactone | 77 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 33 |
| Ozempic | Semaglutide | 72 | 13 |
| Januvia | Sitagliptin Phosphate | 71 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 12 |
| Valacyclovir | Valacyclovir Hcl | 70 | 21 |
| Methotrexate | Methotrexate Sodium | 69 | 11 |
| Celecoxib | Celecoxib | 67 | 21 |
| Farxiga | Dapagliflozin Propanediol | 67 | suppressed |
| Olanzapine | Olanzapine | 67 | 13 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 65 | suppressed |
| Cephalexin | Cephalexin | 64 | 51 |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 14 |
| Hydrocortisone | Hydrocortisone | 64 | 35 |
| Rybelsus | Semaglutide | 64 | suppressed |
| Lamotrigine | Lamotrigine | 63 | 13 |
| Myrbetriq | Mirabegron | 62 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 21 |
| Bupropion Xl | Bupropion Hcl | 59 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 17 |
| Divalproex Sodium | Divalproex Sodium | 58 | 18 |
| Glipizide Er | Glipizide | 56 | 15 |
| Amoxicillin | Amoxicillin | 54 | 49 |
| Estradiol | Estradiol | 53 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 53 | 17 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 18 |
| Methimazole | Methimazole | 51 | suppressed |
| Calcitriol | Calcitriol | 50 | suppressed |
| Diazepam | Diazepam | 50 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 15 |
| Meclizine Hcl | Meclizine Hcl | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 27 |
| Sucralfate | Sucralfate | 43 | 18 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Santyl | Collagenase Clostridium Hist. | 42 | 15 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 42 | suppressed |
| Ketoconazole | Ketoconazole | 41 | 18 |
| Premarin | Estrogens, Conjugated | 41 | suppressed |
| Torsemide | Torsemide | 40 | 12 |
| Dutasteride | Dutasteride | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 16 |
| Primidone | Primidone | 36 | suppressed |
| Mupirocin | Mupirocin | 35 | 17 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Febuxostat | Febuxostat | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Methadone Hcl | Methadone Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 20 |
| Lactulose | Lactulose | 27 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Trulance | Plecanatide | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 11 |
| Nystatin | Nystatin | 23 | 20 |
| Ondansetron Odt | Ondansetron | 23 | 18 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Silodosin | Silodosin | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Repatha Syringe | Evolocumab | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Fluorometholone | Fluorometholone | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Phenytoin | Phenytoin | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 11 |
| Lorazepam Intensol | Lorazepam | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Humira(Cf) Pen | Adalimumab | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nyamyc | Nystatin | 14 | 11 |
| Restasis | Cyclosporine | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Insulin Glargine Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Terconazole | Terconazole | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $992.18 · 50 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, IBSRELA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROQUAD, QULIPTA, REPATHA, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, Veozah, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error